289 related articles for article (PubMed ID: 16284278)
1. Fibrin affinity of erythrocyte-coupled tissue-type plasminogen activators endures hemodynamic forces and enhances fibrinolysis in vivo.
Ganguly K; Goel MS; Krasik T; Bdeir K; Diamond SL; Cines DB; Muzykantov VR; Murciano JC
J Pharmacol Exp Ther; 2006 Mar; 316(3):1130-6. PubMed ID: 16284278
[TBL] [Abstract][Full Text] [Related]
2. Prophylactic fibrinolysis through selective dissolution of nascent clots by tPA-carrying erythrocytes.
Murciano JC; Medinilla S; Eslin D; Atochina E; Cines DB; Muzykantov VR
Nat Biotechnol; 2003 Aug; 21(8):891-6. PubMed ID: 12845330
[TBL] [Abstract][Full Text] [Related]
3. Blood clearance and activity of erythrocyte-coupled fibrinolytics.
Ganguly K; Krasik T; Medinilla S; Bdeir K; Cines DB; Muzykantov VR; Murciano JC
J Pharmacol Exp Ther; 2005 Mar; 312(3):1106-13. PubMed ID: 15525799
[TBL] [Abstract][Full Text] [Related]
4. The glycocalyx protects erythrocyte-bound tissue-type plasminogen activator from enzymatic inhibition.
Ganguly K; Murciano JC; Westrick R; Leferovich J; Cines DB; Muzykantov VR
J Pharmacol Exp Ther; 2007 Apr; 321(1):158-64. PubMed ID: 17215448
[TBL] [Abstract][Full Text] [Related]
5. Clot penetration and retention by plasminogen activators promote fibrinolysis.
Marcos-Contreras OA; Ganguly K; Yamamoto A; Shlansky-Goldberg R; Cines DB; Muzykantov VR; Murciano JC
Biochem Pharmacol; 2013 Jan; 85(2):216-22. PubMed ID: 23098998
[TBL] [Abstract][Full Text] [Related]
6. Fibrin-specificity of a plasminogen activator affects the efficiency of fibrinolysis and responsiveness to ultrasound: comparison of nine plasminogen activators in vitro.
Sakharov DV; Barrertt-Bergshoeff M; Hekkenberg RT; Rijken DC
Thromb Haemost; 1999 Apr; 81(4):605-12. PubMed ID: 10235448
[TBL] [Abstract][Full Text] [Related]
7. An experimental and theoretical study on the dissolution of mural fibrin clots by tissue-type plasminogen activator.
Wootton DM; Popel AS; Alevriadou BR
Biotechnol Bioeng; 2002 Feb; 77(4):405-19. PubMed ID: 11787013
[TBL] [Abstract][Full Text] [Related]
8. Human complement receptor type 1-directed loading of tissue plasminogen activator on circulating erythrocytes for prophylactic fibrinolysis.
Zaitsev S; Danielyan K; Murciano JC; Ganguly K; Krasik T; Taylor RP; Pincus S; Jones S; Cines DB; Muzykantov VR
Blood; 2006 Sep; 108(6):1895-902. PubMed ID: 16735601
[TBL] [Abstract][Full Text] [Related]
9. Tissue plasminogen activator (tPA) inhibits plasmin degradation of fibrin. A mechanism that slows tPA-mediated fibrinolysis but does not require alpha 2-antiplasmin or leakage of intrinsic plasminogen.
Wu JH; Diamond SL
J Clin Invest; 1995 Jun; 95(6):2483-90. PubMed ID: 7769094
[TBL] [Abstract][Full Text] [Related]
10. Effects of intra-abdominal administration of recombinant tissue plasminogen activator on coagulation, fibrinolysis and inflammatory responses in experimental polymicrobial peritonitis.
van Veen SQ; Meijers JC; Levi M; van Gulik TM; Boermeester MA
Shock; 2007 May; 27(5):534-41. PubMed ID: 17438459
[TBL] [Abstract][Full Text] [Related]
11. Highly stable plasminogen activator inhibitor type one (VLHL PAI-1) protects fibrin clots from tissue plasminogen activator-mediated fibrinolysis.
Jankun J; Aleem AM; Selman SH; Skrzypczak-Jankun E; Lysiak-Szydlowska W; Grafos N; Fryer HJ; Greenfield RS
Int J Mol Med; 2007 Nov; 20(5):683-7. PubMed ID: 17912461
[TBL] [Abstract][Full Text] [Related]
12. Biochemical and biophysical conditions for blood clot lysis.
Sabovic M; Blinc A
Pflugers Arch; 2000; 440(5 Suppl):R134-6. PubMed ID: 11005642
[TBL] [Abstract][Full Text] [Related]
13. Modification of fibrinogen by homocysteine thiolactone increases resistance to fibrinolysis: a potential mechanism of the thrombotic tendency in hyperhomocysteinemia.
Sauls DL; Lockhart E; Warren ME; Lenkowski A; Wilhelm SE; Hoffman M
Biochemistry; 2006 Feb; 45(8):2480-7. PubMed ID: 16489740
[TBL] [Abstract][Full Text] [Related]
14. Binding of synthetic B knobs to fibrinogen changes the character of fibrin and inhibits its ability to activate tissue plasminogen activator and its destruction by plasmin.
Doolittle RF; Pandi L
Biochemistry; 2006 Feb; 45(8):2657-67. PubMed ID: 16489759
[TBL] [Abstract][Full Text] [Related]
15. Bispecific monoclonal antibodies produced by somatic cell fusion increase the potency of tissue plasminogen activator.
Branscomb EE; Runge MS; Savard CE; Adams KM; Matsueda GR; Haber E
Thromb Haemost; 1990 Oct; 64(2):260-6. PubMed ID: 2125375
[TBL] [Abstract][Full Text] [Related]
16. The spatial dynamics of fibrin clot dissolution catalyzed by erythrocyte-bound vs. free fibrinolytics.
Gersh KC; Zaitsev S; Muzykantov V; Cines DB; Weisel JW
J Thromb Haemost; 2010 May; 8(5):1066-74. PubMed ID: 20149071
[TBL] [Abstract][Full Text] [Related]
17. Fibrin-specific and effective clot lysis requires both plasminogen activators and for them to be in a sequential rather than simultaneous combination.
Pannell R; Li S; Gurewich V
J Thromb Thrombolysis; 2017 Aug; 44(2):210-215. PubMed ID: 28600623
[TBL] [Abstract][Full Text] [Related]
18. Incorporation of fragment X into fibrin clots renders them more susceptible to lysis by plasmin.
Schaefer AV; Leslie BA; Rischke JA; Stafford AR; Fredenburgh JC; Weitz JI
Biochemistry; 2006 Apr; 45(13):4257-65. PubMed ID: 16566600
[TBL] [Abstract][Full Text] [Related]
19. [Functional characterization of a monoclonal antibody which interferes with the binding of t-PA to fibrin].
Orbe J; Montes R; Chordá C; Páramo JA; Rocha E
Sangre (Barc); 1994 Aug; 39(4):261-6. PubMed ID: 7985055
[TBL] [Abstract][Full Text] [Related]
20. Lytic resistance of fibrin containing red blood cells.
Wohner N; Sótonyi P; Machovich R; Szabó L; Tenekedjiev K; Silva MM; Longstaff C; Kolev K
Arterioscler Thromb Vasc Biol; 2011 Oct; 31(10):2306-13. PubMed ID: 21737785
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
